PharmacoEconomics & Outcomes News 792, p34 - 2 Dec 2017 NICE not recommending teduglutide for SBS In draft guidance, the UK National Institute for Health and Care Excellence (NICE) has not recommended teduglutide (Revestive) for the treatment of short bowel syndrome (SBS) within the NHS, reported Selina McKee in PharmaTimes. NICE’s appraisal committee found that although teduglutide reduces the requirement for intravenous nutrition in patients with short bowel syndrome, it does not eliminate the need. Moreover, the estimated incremental cost- effectiveness ratio for teduglutide was £193 549 per QALY gained in adults, which exceeded NICE’s willingness-to-pay threshold for NHS funding. * National Health Service McKee S. NICE turns down Shire’s Revestive for bowel condition Pharma Times : 14 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/ nice_turns_down_shires_revestive_for_bowel_condition_1211408 803283335 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera